40276
Hydrofluoric acid
49.5-50.5%
Synonym(s):
HF
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
HF
CAS Number:
Molecular Weight:
20.01
UNSPSC Code:
12352106
PubChem Substance ID:
EC Number:
231-634-8
MDL number:
Assay:
49.5-50.5%
vapor density
1.27 (vs air)
vapor pressure
25 mmHg ( 20 °C)
assay
49.5-50.5%
CofA
specification on request
density
1.15 g/mL at 25 °C (lit.)
SMILES string
[H+].[F-]
InChI
1S/FH/h1H
InChI key
KRHYYFGTRYWZRS-UHFFFAOYSA-N
General description
HF is a colorless inorganic acid. Hydrogen fluoride may be formed by reacting calcium fluoride and sulfuric acid at 200oC. The fluoride in the acid has very high affinity to silicon, making it useful in etching or removal of silicon.
Application
Industrial uses of HF include etching or polishing glass, ceramics and silicon surfaces. HF may be used to etch silica capillaries for it behave as a filter and an integrated nanofluidic device for the stacking of DNA and proteins. Dentin and ceramic inlays may be etched with HF for better adhesive bonding. Nanohydroxyapatite was etched with 0.5%HF prior to measuring its morphological and mechanical properties.
Still not finding the right product?
Explore all of our products under Hydrofluoric acid
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 1 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Eye Dam. 1 - Skin Corr. 1A
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Faceshields, Gloves, Goggles, type ABEK (EN14387) respirator filter
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Faiez Zannad et al.
European journal of heart failure, 17(7), 735-742 (2015-04-29)
Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after
Ian Ford et al.
International journal of cardiology, 184, 163-169 (2015-02-24)
We identified easily obtained baseline characteristics associated with outcomes in patients with chronic heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in the SHIFT trial, and used them to develop a prognostic model. We selected the
Philip J Millar et al.
Circulation, 131(5), 459-468 (2014-12-04)
Muscle sympathetic activation in heart failure with reduced ejection fraction (HFrEF) has been attributed, on the basis of multiunit recordings, to attenuated inhibitory feedback from stretch-sensitive cardiopulmonary mechanoreceptors. However, such preparations integrate 2 populations of single units exhibiting directionally opposite